Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT
Zur Ablage hinzufügen
  Lokale TagsFreigabegeschichteDetailsÜbersicht

Freigegeben
Poster

Monitoring neoadjuvant chemotherapy in breast cancer patients using CEST and 31P-MRS at 7 tesla

MPG-Autoren
/persons/resource/persons214560

Zaiss,  M
Max Planck Institute for Biological Cybernetics, Max Planck Society;
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;

Externe Ressourcen

Link
(beliebiger Volltext)

Volltexte (beschränkter Zugriff)
Für Ihren IP-Bereich sind aktuell keine Volltexte freigegeben.
Volltexte (frei zugänglich)
Es sind keine frei zugänglichen Volltexte in PuRe verfügbar
Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Krikken, E., Khlebnikov, V., Zaiss, M., van der Kemp, W., van der Velden, T., van Laarhoven, H., et al. (2017). Monitoring neoadjuvant chemotherapy in breast cancer patients using CEST and 31P-MRS at 7 tesla. Poster presented at 25th Annual Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine (ISMRM 2017), Honolulu, HI, USA.


Zitierlink: https://hdl.handle.net/21.11116/0000-0000-C4D9-E
Zusammenfassung
Treatment monitoring is of importance for breast cancer patients receiving systemic therapy. Metabolic imaging methods such as CEST and 31P-MRS may have potential to predict treatment efficacy in an early stage of the treatment. In this study we assessed the amide proton transfer (APT) signal and the pH change in breast cancer patients before and after the first cycle of neoadjuvant chemotherapy to explore the relation between APT and pH. We observed changes in both the APT signal and the pH between the two measurements. These changes may serve as biomarkers for predicting treatment response to NAC in an early stage.